Get started
Author

Ramil Abdrashitov

ORCID: 0009-0003-4734-2841
Observed ORCID: 0009-0003-4734-2841
OpenAlex ID: A5065195399
Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial
2023 · Shukui Qin, Masatoshi Kudo, et al. · JAMA Oncology · 292
PDF
A phase III, randomized, open-label, multicenter, global study of durvalumab and bacillus calmette-guérin (BCG) versus BCG alone in high-risk, BCG-naïve non-muscle-invasive bladder cancer (NMIBC) patients (POTOMAC).
2019 · Maria De Santis, Ramil Abdrashitov, et al. · Journal of Clinical Oncology · 22
Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study
2024 · Richard S. Finn, Masatoshi Kudo, et al. · Liver Cancer · 16
PDF
First-in-human study of BG-C9074, a B7-H4-targeting ADC in patients with advanced solid tumors: Preliminary results of the dose-escalation phase.
2025 · Cesar Augusto Perez, Linda R. Mileshkin, et al. · Journal of Clinical Oncology · 7
Clinical Pharmacology Overview of Tislelizumab in Patients With Advanced Tumors With a Focus on Racial Impact
2025 · Tian Yu, Chi‐Yuan Wu, et al. · Clinical and Translational Science · 4
PDF
Alternative Dosing Regimens of Tislelizumab Using a Pharmacometrics Model‐Based Approach
2025 · Ahsan Rizwan, Hugh Giovinazzo, et al. · Clinical and Translational Science · 3
PDF
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population.
2023 · Richard S. Finn, Shukui Qin, et al. · Journal of Clinical Oncology · 2
First-in-human study of BG-C9074 (B7-H4–targeting ADC) in advanced solid tumors: Dose escalation and safety expansion.
2026 · Binghe Xu, Linda R. Mileshkin, et al. · Journal of Clinical Oncology · 1
PDF
Subcutaneously Administered Tislelizumab in Locally Advanced or Metastatic Non–Small Cell Lung Cancer: Pharmacokinetics and Safety Results from the BGB-A317-103 Phase I Study
2026 · Minjiang Chen, Iurie Bulat, et al. · Clinical Cancer Research · 1
PDF
A phase 2 study of the OX40 agonist BGB-A445, in combination with docetaxel or BGB-15025, an HPK1 inhibitor, in patients with NSCLC pretreated by anti-PD-(L)1 antibodies.
2025 · Tae Min Kim, Haiyan Liu, et al. · Journal of Clinical Oncology · 1
BGB-A317-212: A multicenter, open-label, phase II study to evaluate the efficacy and safety of tislelizumab in combination with lenvatinib in patients with selected solid tumors.
2024 · Yufei Liu, Zhisong He, et al. · Journal of Clinical Oncology · 1
Model‐Informed Development of a Subcutaneous Formulation of Tislelizumab: Phase 1 Pharmacokinetics in Patients With Cancer
2026 · Xiangyu Liu, Ye Guan, et al. · Clinical and Translational Science
Data from Subcutaneously Administered Tislelizumab in Locally Advanced or Metastatic Non–Small Cell Lung Cancer: Pharmacokinetics and Safety Results from the BGB-A317-103 Phase I Study
2026 · Minjiang Chen, Iurie Bulat, et al.
Supplementary Data1 from Subcutaneously Administered Tislelizumab in Locally Advanced or Metastatic Non–Small Cell Lung Cancer: Pharmacokinetics and Safety Results from the BGB-A317-103 Phase I Study
2026 · Minjiang Chen, Iurie Bulat, et al.
Consideration of adjusted ideal body weight dosing in BG-C9074 (B7-H4–targeting ADC) from pharmacokinetics, efficacy, and safety perspectives.
2026 · Hugh Giovinazzo, Ramil Abdrashitov, et al. · Journal of Clinical Oncology
Final analysis of a multicenter, open-label, phase 2 study evaluating the efficacy and safety of tislelizumab (TIS) in combination with fruquintinib (F) in patients (pts) with selected solid tumors.
2025 · Keun-Wook Lee, Yanqiao Zhang, et al. · Journal of Clinical Oncology
PDF
Alternative dosing regimens of tislelizumab proposed using modeling and simulation.
2025 · Ahsan Rizwan, Tian Yu, et al. · Journal of Clinical Oncology
PDF
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population.
2023 · Richard S. Finn, Shukui Qin, et al. · JCO Global Oncology
PDF
Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): The RATIONALE-301 European/North American (EU/NA) subgroup.
2023 · Arndt Vogel, Tim Meyer, et al. · Journal of Clinical Oncology
Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS).
2023 · Masatoshi Kudo, Richard S. Finn, et al. · Journal of Clinical Oncology
Impact of baseline liver function on overall survival (OS) and safety in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS): results from the RATIONALE-301 study
2023 · Masatoshi Kudo, Arndt Vogel, et al. · Journal of Hepatology
Association of tumor response with survival in patients with unresectable hepatocellular carcinoma treated with first-line tislelizumab versus sorafenib: results from the RATIONALE-301 study
2023 · Tim Meyer, Richard S. Finn, et al. · Journal of Hepatology
Works count: 22
Citation count: 350
H-index: 4
I10-index: 3
Year
Topic
Type